Search results
AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial
Clinical Trials Arena via Yahoo Finance· 1 day agoAstraZeneca and Daiichi Sankyo have reported high-level overall survival (OS) results from the Phase...
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Kingsview Wealth Management LLC
ETF DAILY NEWS· 6 days agoKingsview Wealth Management LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.3% during the 4th quarter, according to the company in its most recent disclosure ...
Here's Why We Think AstraZeneca (LON:AZN) Is Well Worth Watching
Simply Wall St. via Yahoo Finance· 4 days agoIf this kind of company isn't your style, you like companies that generate revenue, and even earn...
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients
Market Watch· 23 hours agoAstraZeneca said its experimental drug for non-small cell lung cancer, jointly developed with Japan's Daiichi Sankyo, showed improvement in progression-free survival in its ...
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Zacks via Yahoo Finance· 21 hours agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
Misleading Claims on Well-Known Rare Risk of AstraZeneca COVID-19 Vaccine - FactCheck.org
FactCheck.org· 5 days agoA rare risk of dangerous blood clots associated with the AstraZeneca COVID-19 vaccine was identified and reported in early 2021. This month, the company announced it was pulling ...
AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody
Pharmaceutical Technology via Yahoo Finance· 5 days agoAstraZeneca has entered a worldwide licence and option agreement with Nona Biosciences for a...
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report...
Benzinga· 23 hours agoWestern pharmaceutical companies and investors are driving a record number of licensing deals with...
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Zacks via Yahoo Finance· 4 days agoAstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer...
AstraZeneca's new 2030 targets are bold attempt to reach for the stars, say analysts
Proactive Investors· 7 days agoAfter AstraZeneca PLC (LSE:AZN) unveiled new sales and profit targets for the end of the decade,...